Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
non-small cell lung cancer
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Specific ALK variants may be linked to the development of ALK resistance mutations and poor clinical outcomes in patients with non-small cell lung cancer.
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
Immunotherapy treatment past progression for patients with advanced lung cancer may account for 29% of total treatment costs, without clear value for most patients, according to a presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium.
Targeted next-generation sequencing may accurately estimate tumor mutation burden in NSCLC, which may further shed light on the likelihood of benefit from immune checkpoint inhibitors in individual patients.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
Adjuvant EGFR TKI treatment for patients with EGFR-mutant NSCLC after complete resection offers a significant disease-free survival advantage, according to a recent meta-analysis.